Anavex Taps European Healthcare Titan for Board, Signaling Global Ambitions

NEW YORK, NY – February 23, 2026 – Anavex Life Sciences Corp. (Nasdaq: AVXL) has made a significant strategic move to bolster its leadership, appointing Dr. Axel Paeger, a titan of European healthcare management, to its Board of Directors. The appointment, announced today, is seen by industry observers as a clear signal of Anavex's intent to navigate the complex European market as it advances its late-stage treatments for devastating central nervous system (CNS) disorders like Alzheimer's and Parkinson's disease.

Dr. Paeger is the founder and CEO of the AMEOS Group, a dominant force in European healthcare. His addition to the board brings a wealth of operational expertise at a pivotal moment for the clinical-stage biopharmaceutical company.

“We are delighted to welcome Dr. Paeger to our Board of Directors at Anavex,” said Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex. “Dr. Paeger brings three decades of strong leadership experience in the healthcare industry, offering invaluable guidance as we continue to advance Anavex’s mission of developing new medicines for the treatment of neurological disorders and progress our innovative pipeline. His extensive knowledge of patient care will be instrumental in shaping Anavex’s strategic evolution with a focus on progressing our late-stage candidates and bringing potential new therapies to people living with CNS disorders.”

A Bridge to the European Market

Dr. Paeger’s background is not that of a typical biopharma director. He is an architect of healthcare delivery systems. Since founding AMEOS as a startup in 2002, he has built it into a behemoth with 85 hospitals and polyclinics, employing over 19,000 people and serving half a million patients annually. Crucially for Anavex, AMEOS is the market leader for inpatient psychiatric care in the lucrative DACH region (Germany, Austria, Switzerland) and a major provider of neurological care.

This deep-rooted experience in the European healthcare landscape is invaluable for a company like Anavex. As it moves its lead candidate, ANAVEX®2-73 (blarcamesine), through the final stages of clinical development for Alzheimer's, the company has already signaled its global intentions. Anavex has held a "Patient and Caregiver Adboard Europe" and presented at the Alzheimer Europe Conference, indicating a concerted effort to understand and penetrate this key market.

Dr. Paeger's hands-on knowledge of European regulatory environments, reimbursement pathways, and hospital procurement processes could provide Anavex with a significant competitive advantage. His expertise extends beyond boardroom theory to the practical realities of getting a new therapy to patients within complex, state-run and private healthcare systems.

From Patient Care to Pipeline Strategy

The appointment also underscores a growing trend in the biopharmaceutical industry: integrating real-world patient care expertise directly into corporate strategy. Dr. Paeger's career began with clinical medicine before he transitioned to management, driven by a desire to improve hospital operations for the benefit of patients. This patient-centric philosophy is echoed in his statement on the appointment.

“Anavex has developed an innovative patient-oriented precision medicine approach in neurology for potential transformative treatment options in Alzheimer’s, Parkinson’s, as well as neurodevelopmental disorders,” said Dr. Paeger. “I’m looking forward to collaborating closely with the board to help advance the Company’s strategy for all stakeholders, including patients, practitioners and stockholders.”

This perspective is critical as Anavex advances its pipeline. The company's lead candidate, blarcamesine, is an oral drug, a potential convenience advantage for patients and caregivers over the infused amyloid-targeting therapies currently on the market. Understanding the daily challenges of patients with Alzheimer's, Parkinson's, and Rett syndrome—all core areas for both Anavex and AMEOS—can directly influence clinical trial design, help define meaningful endpoints, and shape post-approval patient support programs. Dr. Paeger's experience managing facilities that care for these exact patient populations provides a direct line of sight from the lab to the patient's bedside.

Fortifying for a Competitive Late-Stage Push

Anavex is entering a critical phase. The company recently announced positive topline results from its Phase 2b/3 study of blarcamesine in Alzheimer's disease, meeting its primary and key secondary endpoints. Its pipeline also includes ANAVEX®3-71, which has shown promise in early trials for schizophrenia. This progress, however, is set against a fiercely competitive CNS landscape.

In Alzheimer's, Anavex must contend with recently approved treatments from major pharmaceutical players, with a host of other oral therapies also in late-stage development. The Parkinson's and Rett syndrome markets are similarly active. To succeed, Anavex needs more than promising science; it requires flawless execution in late-stage trials, regulatory engagement, and eventual commercialization.

Strengthening the board with a seasoned operator like Dr. Paeger is a classic move for a company preparing for this transition. His experience in scaling an organization, managing large budgets, and navigating complex operational hurdles provides critical governance and oversight. This move comes as Anavex has shored up its financial position, recently reporting a quarterly earnings beat and highlighting a balance sheet with no debt, providing the financial runway needed for its ambitious clinical programs. While the company's stock has seen volatility, analyst price targets remain significantly higher than its current valuation, suggesting Wall Street sees potential for a major turnaround pending clinical and regulatory success. Dr. Paeger's appointment adds a layer of seasoned leadership that could help unlock that value and steer the company through the high-stakes journey from clinical development to commercial reality.